Compare VTIX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTIX | PLRX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | 39 | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.9M | 68.7M |
| IPO Year | N/A | 2020 |
| Metric | VTIX | PLRX |
|---|---|---|
| Price | $1.51 | $1.06 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 690.1K | ★ 690.9K |
| Earning Date | 08-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.45 | $1.05 |
| 52 Week High | $9.00 | $1.95 |
| Indicator | VTIX | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 39.58 |
| Support Level | N/A | N/A |
| Resistance Level | $4.51 | $1.37 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 6.85 | 9.09 |
Virtuix Holdings Inc pioneers movement in AI-generated worlds, both imaginary and real. The company is the creator of Omni, a brand of omni-directional treadmills that enable users to walk and run in 360 degrees inside virtual reality (VR) games, digital twins, and other applications. Its technology operates at the intersection of gaming, fitness, and enterprise VR. Its products include Omni Pro, Omni Arena, and Omni One. Its business integrates a consumer and enterprise VR hardware platform anchored by its flagship Omni One product with a defense-oriented simulation system, Virtual Terrain Walk (VTW), targeting next-generation immersive mission planning.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.